Skip to main content
. 2009 Jan 26;30(2):242–250. doi: 10.1038/aps.2008.28

Table 1. General characteristics and clinical parameters of healthy control subjects and type 2 diabetic patients in our cross-sectional study. Data were expressed as Mean±SD or as geometric means (95% CI). bP<0.05, cP<0.01 vs control; eP<0.05, fP<0.01 vs normoalbuminuria; iP<0.01 vs microalbuminuria.

  Control subjects Normoalbuminuria Type 2 diabetes Microalbuminuria Clinical proteinuria
Gender (M/F) 46 (21/25) 59 (36/23) 68 (38/30) 39 (22/17)
Age (years) 57.41±7.95 57.03±10.15 58.16±9.75 59.13±9.26
Duration of diabetes (years) 6.97±6.68 7.37±7.28 10.03±5.57e
SBP (mmHg) 120±13 129±18b 134±17c 149±19cf
DBP (mmHg) 79±10 79±8 82±10f 87±11ci
BMI (kg/m2) 23.41±2.61 24.71±2.83 25.10±3.55 24.68±4.43
HbA1c (%) 5.27±0.25 8.34±2.19c 8.23±1.90c 8.47±2.31c
FPG (mmol/L) 5.03±0.38 8.35±2.85c 8.05±2.12c 8.66±3.27c
PPG2H (mmol/L) 5.67±1.05 13.14±4.00c 13.5±4.64c 12.87±5.38c
TC (mmol/L) 4.83±0.81 4.92±1.09 5.09±1.10 4.92±1.59
LDL-c (mmol/L) 2.76±0.78 3.03±0.76 3.21±0.99 2.83±1.12
TG (mmol/L) 1.54±1.40 1.82±1.20 2.58±2.55 2.27±2.81
HDL-c (mmol/L) 1.56±0.38 1.23±0.35c 1.27±0.42c 1.13±0.28c
AER (μg/min) 5.05 (3.48–8.14) 7.12 (4.26–10.20) 47.35 (39.24–57.14)cf 721.6 (518.1–1005)cfi
eGFR (mL·min−1/1.73 m2) 98.15±18.48 102.70±21.44 97.27±28.89 62.87±30.66cfi
Hypertension 0 32 (54.24%) 46 (67.65%) 39 (100%)
ACEI/ARB treatment in hypertensive patients 0 18 (56.25%) 25 (55%) 21 (54%)
DR (non/simplex/proliferative) 41/18/0 37/31/0 0/23/16

Data were analyzed using one-way ANOVA. Pearson correlation analyses were used to determine the association between urinary VEGF and other parameters. BMI: body-mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; FPG: fasting plasma glucose; PPG2H: 2-h postprandial plasma glucose; TC: total cholesterol; LDL-c: low-density lipoprotein-cholesterol; TG: triglyceride; HDL-c: high-density lipoprotein-cholesterol; eGFR: estimated glomerular filtrate rate; AER: albumin excretion rate.